Replimune Group, Inc. (REPL): Price and Financial Metrics
GET POWR RATINGS... FREE!
REPL Stock Price Chart Interactive Chart >
REPL Price/Volume Stats
| Current price | $18.92 | 52-week high | $29.52 |
| Prev. close | $19.24 | 52-week low | $13.05 |
| Day low | $18.82 | Volume | 860,400 |
| Day high | $19.58 | Avg. volume | 586,742 |
| 50-day MA | $23.64 | Dividend yield | N/A |
| 200-day MA | $20.90 | Market Cap | 1.07B |
Replimune Group, Inc. (REPL) Company Bio
Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.
Latest REPL News From Around the Web
Below are the latest news stories about REPLIMUNE GROUP INC that investors may wish to consider to help them evaluate REPL as an investment opportunity.
Replimune to Present at Two Upcoming Investor ConferencesWOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: Barclays Global Healthcare ConferenceDate: Wednesday, March 15, 2023Fireside Chat Time: 2:05 pm EDTLocation: The Loews Miami Beach Hotel, Miam |
Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerReplimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Replimune Group, Inc. (REPL) is on the Move, Here's Why the Trend Could be SustainableReplimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate UpdateStrengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline data from the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be announced in Q3 2023 along with updates from ongoing RP1 skin cancer cohorts including anti-PD1 failed non-melanoma skin cancer (CSCC predominant) and the RP1 monotherap |
Replimune to Present at the Virtual SVB Securities Global Biopharma ConferenceWOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET. A simultaneous webcast will be available in the Investors section of Repl |
REPL Price Returns
| 1-mo | -11.30% |
| 3-mo | -31.87% |
| 6-mo | 9.55% |
| 1-year | 13.50% |
| 3-year | 91.69% |
| 5-year | N/A |
| YTD | -30.44% |
| 2022 | 0.37% |
| 2021 | -28.96% |
| 2020 | 165.85% |
| 2019 | 43.50% |
| 2018 | N/A |
Loading social stream, please wait...